[{"id":"da-paper-clarity-ad","kind":"paper","name":"Lecanemab in Early Alzheimer’s Disease (CLARITY AD)","aka":[],"tldr":"The published CLARITY AD paper reports the phase 3 lecanemab trial in early Alzheimer’s disease. Read the paper and the FDA communication together.","summary":"Randomised, placebo-controlled trial in early symptomatic Alzheimer’s disease with confirmed amyloid. ARIA was the principal safety theme. This atlas records the trial and this paper as separate objects so a reader can walk from the product to the study to the publication.","asOf":"2026-09-21","links":[{"label":"DOI","url":"https://doi.org/10.1056/NEJMoa2212948"},{"label":"ClinicalTrials.gov NCT03887455","url":"https://clinicaltrials.gov/study/NCT03887455"}],"tags":["dementia-atlas"],"related":[],"cancers":["alzheimers-disease"],"sections":[],"technologies":[],"targets":[],"drugs":["da-lecanemab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["da-trial-clarity-ad"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["da-journal-nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2023,"doi":"10.1056/NEJMoa2212948","authors":"van Dyck CH, et al.","paperType":"rct","findings":["Primary clinical endpoint favoured lecanemab versus placebo in the enrolled population.","ARIA occurred, more often in ApoE ε4 carriers."],"whatItMeans":"This is the main published efficacy trial behind the US traditional approval of lecanemab. A mean scale change is not a promise for one person.","caveats":["Trial cohorts are not the same as mixed-pathology clinic populations.","Individual benefit cannot be read from a group mean."]}]